MX2020005535A - Combinacion de terapias local y sistemica para tratamiento mejorado de condiciones dermatologicas. - Google Patents
Combinacion de terapias local y sistemica para tratamiento mejorado de condiciones dermatologicas.Info
- Publication number
- MX2020005535A MX2020005535A MX2020005535A MX2020005535A MX2020005535A MX 2020005535 A MX2020005535 A MX 2020005535A MX 2020005535 A MX2020005535 A MX 2020005535A MX 2020005535 A MX2020005535 A MX 2020005535A MX 2020005535 A MX2020005535 A MX 2020005535A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- treatment
- cox
- inflammatory
- antibodies
- Prior art date
Links
- 238000009121 systemic therapy Methods 0.000 title 1
- 230000000295 complement effect Effects 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 abstract 1
- 108010032595 Antibody Binding Sites Proteins 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 abstract 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 abstract 1
- 102000013462 Interleukin-12 Human genes 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 102000013691 Interleukin-17 Human genes 0.000 abstract 1
- 108050003558 Interleukin-17 Proteins 0.000 abstract 1
- 102000013264 Interleukin-23 Human genes 0.000 abstract 1
- 108010065637 Interleukin-23 Proteins 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 229960001102 betamethasone dipropionate Drugs 0.000 abstract 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 abstract 1
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 abstract 1
- 229960002882 calcipotriol Drugs 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 1
- 229960004419 dimethyl fumarate Drugs 0.000 abstract 1
- 229960002311 dithranol Drugs 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 229960000785 fluocinonide Drugs 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 abstract 1
- 229960001330 hydroxycarbamide Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940124829 interleukin-23 Drugs 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 229930187593 rose bengal Natural products 0.000 abstract 1
- -1 rose bengal Chemical class 0.000 abstract 1
- 229940081623 rose bengal Drugs 0.000 abstract 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 abstract 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describe un tratamiento para las dermatosis inflamatorias, como la psoriasis y la dermatitis atópica (eczema), que utiliza la administración tópica de un xanteno halogenado, como rosa bengala, junto con la administración de una o más terapias dermatológicas sistémicas dirigidas complementarias, preferentemente una terapia que aborda la via inflamatoria y otra que es un NSAID que es un inhibidor de COX - 1 y/o/ COX-2. Los ejemplos de ingredientes terapéuticos sistémicos dirigidos complementarios incluyen corticosteroides incluyendo dipropionato de betametasona y fluocinomida; ditranol; análogos de vitamina D, incluyendo calcipotriol; y retinoides no biológicos inclyendo metotrexato ciclosporina, hidroxicarbamida y fumaratos incluyendo dimetilfumarato; así como uno o más biológicos, incluyendo anticuerpos o porciones de anticuerpo que contienen paratopos para TNF-a, anticuerpos para citoquinas proinflamatorias interleucina-12, interlucina-23 e interlucina-17 e inhibidores del TNF. Tambien se describe el tratamiento de otro tejido epitelial, como el revestimiento del intestino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592086P | 2017-11-29 | 2017-11-29 | |
| PCT/US2018/063094 WO2019108814A1 (en) | 2017-11-29 | 2018-11-29 | Combination of local and systemic therapies for enhanced treatment of dermatologic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005535A true MX2020005535A (es) | 2021-01-15 |
Family
ID=66634401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005535A MX2020005535A (es) | 2017-11-29 | 2018-11-29 | Combinacion de terapias local y sistemica para tratamiento mejorado de condiciones dermatologicas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11426379B2 (es) |
| EP (1) | EP3700520B1 (es) |
| JP (1) | JP7166339B2 (es) |
| KR (1) | KR20200083538A (es) |
| CN (1) | CN111787918A (es) |
| AU (1) | AU2018375425B2 (es) |
| CA (1) | CA3083789A1 (es) |
| MX (1) | MX2020005535A (es) |
| WO (1) | WO2019108814A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019108814A1 (en) * | 2017-11-29 | 2019-06-06 | The Rockefeller University | Combination of local and systemic therapies for enhanced treatment of dermatologic conditions |
| WO2023245032A2 (en) * | 2022-06-14 | 2023-12-21 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treating pediatric autoimmune neuropsychiatric disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US3330729A (en) | 1963-10-04 | 1967-07-11 | Goodrich Co B F | Sustained release tablet containing medicament admixed in a waterinsoluble acrylic acid cross-linked polymer and selected basic magnesium or calcium diluent |
| US5556992A (en) | 1994-09-02 | 1996-09-17 | Universite De Montreal | Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias |
| US6493570B1 (en) | 1998-11-02 | 2002-12-10 | Photogen, Inc. | Method for improved imaging and photodynamic therapy |
| US5829448A (en) | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
| US6331286B1 (en) | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
| US8974363B2 (en) | 1997-12-11 | 2015-03-10 | Provectus Pharmatech, Inc. | Topical medicaments and methods for photodynamic treatment of disease |
| US6986740B2 (en) * | 1998-11-02 | 2006-01-17 | Xantech Pharmaceuticals, Inc. | Ultrasound contrast using halogenated xanthenes |
| CN1259973C (zh) | 2000-10-25 | 2006-06-21 | 中外制药株式会社 | 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂 |
| WO2004044219A2 (en) | 2002-11-12 | 2004-05-27 | Mercury Therapeutics, Inc. | Xanthene compounds for cancer chemotherapy |
| US20080207738A1 (en) * | 2007-02-28 | 2008-08-28 | Cancure Laboratories, Llc | Drug combinations to treat drug resistant tumors |
| ES2763703T3 (es) * | 2008-04-15 | 2020-05-29 | Sarcode Bioscience Inc | Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes |
| JP6322413B2 (ja) * | 2011-03-10 | 2018-05-09 | プロヴェクタス ファーマテック，インク． | 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ |
| WO2019108814A1 (en) * | 2017-11-29 | 2019-06-06 | The Rockefeller University | Combination of local and systemic therapies for enhanced treatment of dermatologic conditions |
-
2018
- 2018-11-29 WO PCT/US2018/063094 patent/WO2019108814A1/en unknown
- 2018-11-29 US US16/204,832 patent/US11426379B2/en active Active
- 2018-11-29 EP EP18882370.2A patent/EP3700520B1/en active Active
- 2018-11-29 CN CN201880077287.4A patent/CN111787918A/zh active Pending
- 2018-11-29 MX MX2020005535A patent/MX2020005535A/es unknown
- 2018-11-29 KR KR1020207015447A patent/KR20200083538A/ko not_active Application Discontinuation
- 2018-11-29 JP JP2020529170A patent/JP7166339B2/ja active Active
- 2018-11-29 CA CA3083789A patent/CA3083789A1/en active Pending
- 2018-11-29 AU AU2018375425A patent/AU2018375425B2/en active Active
-
2021
- 2021-09-03 US US17/466,600 patent/US20220054449A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019108814A1 (en) | 2019-06-06 |
| EP3700520A4 (en) | 2021-07-28 |
| EP3700520B1 (en) | 2024-05-01 |
| CA3083789A1 (en) | 2019-06-06 |
| US11426379B2 (en) | 2022-08-30 |
| AU2018375425A2 (en) | 2020-06-25 |
| JP2021504386A (ja) | 2021-02-15 |
| US20190160039A1 (en) | 2019-05-30 |
| EP3700520A1 (en) | 2020-09-02 |
| KR20200083538A (ko) | 2020-07-08 |
| US20220054449A1 (en) | 2022-02-24 |
| AU2018375425A1 (en) | 2020-05-28 |
| JP7166339B2 (ja) | 2022-11-07 |
| CN111787918A (zh) | 2020-10-16 |
| AU2018375425B2 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kazandjieva et al. | Drug-induced acne | |
| Łuczaj et al. | The onset of lipid peroxidation in rheumatoid arthritis: consequences and monitoring | |
| MX2020005535A (es) | Combinacion de terapias local y sistemica para tratamiento mejorado de condiciones dermatologicas. | |
| Duntas | The evolving role of selenium in the treatment of graves′ disease and ophthalmopathy | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| MX2017005030A (es) | Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio. | |
| MY171929A (en) | Corticosteroids for the treatment of joint pain | |
| NZ738815A (en) | Topical retinoid compositions | |
| EA201991790A1 (ru) | Терапевтические препараты апремиласта для местного применения | |
| BR112018006817A2 (pt) | método de tratamento do câncer | |
| EA201691808A8 (ru) | Кортикостероидные композиции для местного применения | |
| Moura Rocha et al. | Gastroprotection of (‐)‐α‐bisabolol on acute gastric mucosal lesions in mice: the possible involved pharmacological mechanisms | |
| Iraji et al. | The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris | |
| BR112015024621A2 (pt) | c. novyi para o tratamento de tumores sólidos em seres humanos | |
| EP4345110A3 (en) | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor | |
| Zhang et al. | Tumor vascular disrupting agent 5, 6‐dimethylxanthenone‐4‐acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase | |
| MX2021005801A (es) | Metodos para administrar corticosteroides. | |
| Bärnthaler et al. | Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation | |
| JP2016513650A5 (es) | ||
| MX2023012181A (es) | Anticuerpos anti-cd20 y estructuras car-t. | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| Belcher et al. | LP07 and LLC preclinical models of lung cancer induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting | |
| WO2018067946A8 (en) | METHODS OF TREATING PATIENTS USING RETINOIC ACID ALPHA RECEPTOR AGONIST AND ANTI-CD38 ANTIBODY | |
| CA3046446A1 (en) | Therapies for treating inflammatory disorders | |
| BR112013003064A2 (pt) | agente profilático ou terapêutico para a esteato-hepatite não alcoólica |